References
1. Pai, K., et al., Optimising alkalinisation and its effect on QRS
narrowing in tricyclic antidepressant poisoning. 2022. 88 (2):
p. 723-733.
2. Arango-Dávila, C.A. and H.G. Rincón-Hoyos, Depressive disorder,
anxiety disorder and chronic pain: Multiple manifestations of a common
clinical and pathophysiological core. Revista Colombiana de Psiquiatría
(English Edition), 2018. 47 (1): p. 46-55.
3. Soleimani, V., et al., Safety and toxicity of silymarin, the major
constituent of milk thistle extract: An updated review. Phytother Res,
2019. 33 (6): p. 1627-1638.
4. Hadi, A., et al., The effects of silymarin supplementation on
metabolic status and oxidative stress in patients with type 2 diabetes
mellitus: A systematic review and meta-analysis of clinical trials.
Complement Ther Med, 2018. 41 : p. 311-319.
5. Gummin, D.D., et al., 2020 Annual Report of the American Association
of Poison Control Centers’ National Poison Data System (NPDS): 38th
Annual Report. Clin Toxicol (Phila), 2021. 59 (12): p.
1282-1501.
6. Gummin, D.D., et al., 2017 Annual Report of the American Association
of Poison Control Centers’ National Poison Data System (NPDS): 35th
Annual Report. Clin Toxicol (Phila), 2018. 56 (12): p.
1213-1415.
7. Elsamadisi, P., A. Sclafani, and I.M. Eche, Delayed Cardiotoxicity
From a Massive Nortriptyline Overdose Requiring Prolonged Treatment. J
Pharm Pract, 2020. 33 (4): p. 543-547.
8. Giwa, A. and E. Oey, The return of an old nemesis: Survival after
severe tricyclic antidepressant toxicity, a case report. Toxicol Rep,
2018. 5 : p. 357-362.
9. Pierog, J.E., et al., Tricyclic antidepressant toxicity treated with
massive sodium bicarbonate. Am J Emerg Med, 2009. 27 (9): p.
1168.e3-7.
10. Breyer-Pfaff, U., et al., Antidepressive effect and pharmacokinetics
of amitriptyline with consideration of unbound drug and
10-hydroxynortriptyline plasma levels. 1982. 76 (3): p. 240-244.
11. Lee, S.Y., et al., A case report of a poor metabolizer of CYP2D6
presented with unusual responses to nortriptyline medication. J Korean
Med Sci, 2004. 19 (5): p. 750-2.
12. Shim JC, G.B., Park JH, Yoon YR, Sin JG, Kim JI, Ahn DS, Kim YK, Cha
IJ, Kim YH., Combined therapy of paroxetine and tricyclic antidepressant
in depression of schizophrenic patients. Korean Neuropsychiatr Assoc,
1997. 36 .
13. Karimi, G., et al., ”Silymarin”, a promising pharmacological agent
for treatment of diseases. Iran J Basic Med Sci, 2011. 14 (4):
p. 308-17.
14. Wu, J.-W., L.-C. Lin, and T.-H. Tsai, Drug–drug interactions of
silymarin on the perspective of pharmacokinetics. Journal of
Ethnopharmacology, 2009. 121 (2): p. 185-193.